Ocular Therapeutix Priced, Nasdaq: OCUL
Develops eye therapies using a sustained-release hydrogel platform.
Industry: Health Care
First Day Return: +1.2%
OCUL
Develops eye therapies using a sustained-release hydrogel platform.
| IPO Data | |
|---|---|
| IPO Date | 07/24/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $65 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Bedford, MA, United States |
| Founded | 2006 |
| Employees at IPO | 58 |
| Website www.ocutx.com | |
IPO News for Ocular Therapeutix
Ocular Therapeutix (OCUL) Performance
